Clinical trial
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed…
NCT00091624 · Celgene Corporation, Industry · Completed
Key facts
| NCT number | NCT00091624 |
|---|---|
| Title | A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) |
| Official title | A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) |
| Lead sponsor | Celgene Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 77 |
| Start date | Mar 1, 2003 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Sep 15, 2004 |
| Last update posted | Dec 1, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: